Trial reportJournal of psychopharmacology (Oxford, England)2016
A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.
Trial report in Journal of psychopharmacology (Oxford, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis.Frontiers in psychiatry · 2023Pooled it
- Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.JAMA psychiatry · 2021Pooled it
- Maintenance treatment with antipsychotic drugs for schizophrenia.The Cochrane database of systematic reviews · 2020Pooled it
- The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study.International clinical psychopharmacology · 2026Trial
- Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression.Journal of child and adolescent psychopharmacology · 2021Trial
- Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies.European psychiatry : the journal of the Association of European Psychiatrists · 2021Trial
- Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study.Neuropsychiatric disease and treatment · 2021Trial
- Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia.Psychiatry and clinical neurosciences · 2020Trial
- Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.BMC psychiatry · 2020Trial
- Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.Journal of child and adolescent psychopharmacology · 2017Trial
- Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.The international journal of neuropsychopharmacology · 2017Trial
- Identification of N-debenzisothiazole-lurasidone as an enzymatic degradation product of lurasidone.Journal of analytical toxicology · 2026Article
- Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm.Neuropsychiatric disease and treatment · 2026Article
- Efficacy of lurasidone on anxiety symptoms in patients with schizophrenia: A pooled post hoc analysis of five randomized, placebo-controlled trials.PCN reports : psychiatry and clinical neurosciences · 2025Article
- The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults.International clinical psychopharmacology · 2025Article
- Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies.Annals of general psychiatry · 2024Article
- Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.Drug design, development and therapy · 2023Review
- Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.International journal of environmental research and public health · 2022Article
- Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2022Article
- Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effectiveness of lurasidone as maintenance treatment for schizophrenia.
methodAdults experiencing an acute exacerbation of schizophrenia initially received 12-24 weeks of open-label treatment with lurasidone (40-80 mg/d, flexibly dosed). Patients who maintained clinical stability for ⩾12 weeks were randomized in double-blind fashion to placebo or lurasidone (40-80 mg/d, flexibly dosed) for an additional 28-week treatment period. The primary efficacy endpoint was time to relapse (based on Kaplan-Meier survival analysis).
resultsA total of 676 patients enrolled in the open-label phase; 285 met protocol-specified stabilization criteria and were randomized to lurasidone (N=144) or placebo (N=141). During the open-label phase, mean Positive and Negative Syndrome Scale total score decreased from 90.1 to 54.4 in patients who met clinical stability criteria and were randomized. In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447-0.983); p=0.041). Probability of relapse at the double-blind week 28 endpoint (based on Kaplan-Meier analysis) was 42.2% in the lurasidone group and 51.2% in the placebo group. Minimal changes in weight, lipid, glucose, and prolactin were observed throughout the study.
conclusionsThis multicenter, placebo-controlled, randomized withdrawal study demonstrated the efficacy of lurasidone for the maintenance treatment of patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.